# Suven Life Sciences Limited (SUVEN)

> SUVEN closed at ₹259.50 on 30 Oct 2026, market cap ₹6,851 cr, latest results for the quarter ended 30 Jun 2026. Revenue, profit, ROE, debt, own P/E range and sector-peer comparison from the SEBI filing.

Suven Life Sciences Limited (NSE: SUVEN) closed at ₹259.50 on 30 Oct 2026, +35.5% over one year, against a 52-week range of ₹124.11 – ₹403.35.

In the quarter ended 30 Jun 2026 (consolidated, filed 6 Aug 2026) it reported revenue of ₹4 cr and a net loss of ₹128 cr; revenue grew 91.0% year on year.

No trailing P/E is published: trailing twelve-month earnings are negative (-352 cr), so a P/E has no meaning — a loss-making business is not 'cheap' at a negative multiple. Judge it on revenue growth, cash burn and funding instead.

From the balance sheet dated 31 Mar 2026: return on equity -86.3%, ROCE -85.7%, debt-to-equity 0.00, Piotroski F-score 4 of 9.

Against 65 Healthcare peers on NSE: ROE higher than 0% of 63 sector peers; ROCE higher than 0% of 63 sector peers; Debt / equity lower than 88% of 64 sector peers.

## Key figures

| Figure | Value |
|---|---|
| Last close | ₹259.50 (30 Oct 2026) |
| Change 1 month / 6 months / 1 year | -22.5% / +28.4% / +35.5% |
| 52-week low – high | ₹124.11 – ₹403.35 |
| Market capitalisation | ₹6,851 cr |
| Price / book | 11.58 |
| TTM EPS | ₹-13.35 |
| TTM net profit | ₹-352 cr |
| Quarter revenue | ₹4 cr |
| Quarter net loss | ₹128 cr |
| Revenue growth (YoY) | +91.0% |
| Profit growth (YoY) | -147.7% |
| Return on equity | -86.3% |
| ROCE | -85.7% |
| Debt / equity | 0.00 |
| Current ratio | 17.69 |
| Free cash flow | ₹-307 cr |
| Piotroski F-score | 4 / 9 |
| Average daily turnover (50 days) | ₹17.1 cr |

## Questions

### What were Suven Life Sciences Limited's latest quarterly results?

For the quarter ended 30 Jun 2026, Suven Life Sciences Limited reported revenue of ₹4 cr and a net loss of ₹128 cr (consolidated), filed with the exchange on 6 Aug 2026.

### What is Suven Life Sciences Limited's ROE?

Return on equity is -86.3% based on the balance sheet dated 31 Mar 2026.

### Does Suven Life Sciences Limited have debt?

Debt-to-equity is 0.00 on the balance sheet dated 31 Mar 2026.

### What is SUVEN's 52-week high and low?

Over the last 52 weeks to 30 Oct 2026, SUVEN traded between ₹124.11 and ₹403.35.

Sector: [Healthcare](https://trinetra.trade/sectors/healthcare) · Page: https://trinetra.trade/fundamentals/SUVEN

_TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing._